Research

Hormonal

Once-weekly subcutaneous semaglutide 2.4 mg injection is a cost-effective weight management therapy in the UK compared to diet and exercise alone, yielding an ICER of £14,827/QALY gained.

For patients in the UK with obesity and comorbidities, once-weekly semaglutide 2.4 mg combined with diet and exercise is a cost-effective treatment option approved by NICE. It offers significant health benefits over diet and exercise alone, with a stopping rule to ensure efficacy (5% weight loss at 6 months).

GoodSupportsHIGH confidence
The base case analysis using the STEP 1 trial showed that treatment with semaglutide 2.4 mg s.c. injection was associated with higher total costs and health benefits compared to D&E, with an incremental cost-effectiveness ratio (ICER) of £14,827/QALY gained.
Hera Sandhu et al. · Advances in Therapy · 2023

Why this rating

Based on a validated economic model using data from large phase III randomized controlled trials (STEP 1), though it is a modeling study rather than a direct clinical trial of long-term outcomes.

Source

Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in the United Kingdom

Hera Sandhu et al. · Advances in Therapy · 2023

DOI 10.1007/s12325-022-02423-8

narrative_reviewCited 22×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →